TP53 and intrahepatic cholangiocarcinoma: In addition, ICC patients treated with adjuvant gemcitabine, those with >4% mutant p53–positive cells had longer DFS compared with ICC patients with ≤4% mutant p53 (18.5 vs. 6 months) [49].